Информатика ва ахборот технологиялари

References

1. 
   D. C. Swinney, “Phenotypic vs. targetbased drug discovery for firstinclass medicines,” Clinical Pharmacology and Therapeutics, vol. 93, no. 4, pp. 299–301, 2013.
   
2. 
   D. C. Swinney and J. Anthony, “How were new medicines discovered?,” Nature Reviews. Drug Discovery, vol. 10, no. 7, pp. 507–519, 2011.
   
3. 
   M. Götte, C. Mohr, C. Y. Koo et al., “MiR145dependent tar geting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness,” Oncogene, vol. 29, no. 50, pp. 6569–6580, 2010.
   
4. 
   J. C. Caicedo, S. Cooper, F. Heigwer et al., “Dataanalysis strategies for imagebased cell profiling,” Nature Methods, vol. 14, no. 9, pp. 849–863, 2017.
   
5. 
   S. J. Hassenbusch, R. K. Portenoy, M. Cousins et al., “Polya nalgesic consensus conference 2003: an update on the man agement of pain by intraspinal drug delivery– report of an expert panel,” Journal of Pain and Symptom Management, vol. 27, no. 6, pp. 540–563, 2004.
   
6. 
   P. Schneider, W. P. Walters, A. T. Plowright et al., “Rethink ing drug design in the artificial intelligence era,” Nature Reviews. Drug Discovery, vol. 19, no. 5, pp. 353–364, 2020.
   
7. 
   A. Bender, D. Bojanic, J. W. Davies et al., “Which aspects of HTS are empirically correlated with downstream success?,” Current Opinion in Drug Discovery and Development, vol. 11, no. 3, p. 327, 2008.
   
8. 
   Y. Gilad, K. Nadassy, and H. Senderowitz, “A reliable compu tational workflow for the selection of optimal screening libraries,” Journal of Cheminformatics, vol. 7, no. 1, pp. 1– 17, 2015.
   
9. 
   J. Bajorath, “Extending accessible chemical space for the identification of novel leads,” Expert Opinion on Drug Discov ery, vol. 11, no. 9, pp. 825–829, 2016.
   
10. 
    E. Moen, D. Bannon, T. Kudo, W. Graf, M. Covert, and
    

D. Van Valen, “Deep learning for cellular image analysis,”

Nature Methods, vol. 16, no. 12, pp. 1233–1246, 2019.